These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 6964038

  • 21. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.
    Donehower RC, Karp JE, Burke PJ.
    Cancer Treat Rep; 1986 Sep; 70(9):1059-65. PubMed ID: 3461882
    [Abstract] [Full Text] [Related]

  • 22. Remission-induction regimens in acute nonlymphocytic leukemia.
    Brennan DC, Lewis JP.
    West J Med; 1980 Oct; 133(4):279-88. PubMed ID: 7347042
    [Abstract] [Full Text] [Related]

  • 23. [Myelogenous leukemia in children. ANLL9205 study by Children's Cancer and Leukemia Study Group (CCLSG)].
    Mimaya J, Horikoshi Y, Shimizu H, Maeda H, Koizumi S, Kawakami K, Watanabe A, Utsumi J, Kikuta A, Oka T, Mugishima H, Kawamura N, Gushiken T, Ohta S, Yamamura Y, Ishida Y, Sekine I, Okada N, Fujimoto T.
    Rinsho Ketsueki; 1997 Feb; 38(2):100-7. PubMed ID: 9059063
    [Abstract] [Full Text] [Related]

  • 24. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V.
    Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC, Lin SF, Yao M, Chen TY, Tsao CJ, Chen TP.
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment childhood lymphoblastic leukemia: isolation of a drug resistant and a sensitive cell line.
    Kees UR.
    Cancer Res; 1987 Jun 15; 47(12):3088-91. PubMed ID: 3472651
    [Abstract] [Full Text] [Related]

  • 34. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M.
    Ann Hematol; 2004 Nov 15; 83(11):696-703. PubMed ID: 15322763
    [Abstract] [Full Text] [Related]

  • 35. [High-dose Ara-C treatment of acute leukemia].
    Takaku F.
    Gan To Kagaku Ryoho; 1986 May 15; 13(5):1823-8. PubMed ID: 3707145
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide].
    Kiyama Y, Suzuki G, Masauzi N, Ohizumi H, Kobayashi N, Ogasawara M, Naohara T, Saito M, Higa T, Kasai M.
    Gan To Kagaku Ryoho; 1996 Oct 15; 23(12):1717-20. PubMed ID: 8886052
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.